Nov. 17 at 4:26 PM
RYAM’s 3Q25 results highlight operational progress amid soft markets and set the stage for a recovery in 2026.
🔹 Revenue of
$353M and adjusted EBITDA of
$42M, with losses narrowing sharply Y/Y
🔹 Cellulose Specialties remains the profit driver, with pricing resets targeted for 2026
🔹 Biomaterials projects advancing, including U.S. bioethanol and Altamaha Green Energy JV
🔹 Divestitures of non-core operations planned as RYAM focuses on higher-margin specialties
🔹 Leverage manageable with liquidity of
$140M and FCF expected positive in 4Q
Read Dmitry Silversteyn's full report for more!
https://www.watertowerresearch.com/doc?docID=UR_RYAM_11132025
$RYAM #Biomaterials #Sustainability #EnergyTransition #Renewables #SpecialtyChemicals #SmallCap #Stocks #Investing